Home » Taro rejects Sun Pharma offer
Taro rejects Sun Pharma offer
July 19, 2012
The special committee of the board of directors of Taro Pharmaceutical Industries unanimously rejected the Oct. 18, 2011, unsolicited, non-binding offer from Sun Pharmaceutical Industries—to purchase all of the issued and outstanding shares of Taro not currently held by Sun Pharma for $24.50 per share—as inadequate and not in the best interests of Taro's minority shareholders.
The special committee reached its conclusion after careful consideration, including a thorough review of Taro's business and prospects with its independent financial advisor legal counsel.
Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials
Learn More Here